Chainalysis AI Traces $387M Bitget Hack in Under 10 Minutes 
SoftBank Shares Fall After $10 Billion OpenAI Investment 
Malaysia Aviation Group to Buy Airbus SAE Unit 
Flydubai FZ1073 Co-Pilot Accused of Terror Attack 
MSTR Stock Rises 3% as Strategy Challenges MSCI Bitcoin Stance 
Italgas to Buy 22.5% Stake in Portugal’s Floene for €120 Million 
XRP Ledger Hits 10 Million AI Payments as Bitcoin Retreats 
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal 
Evernorth Set for Nasdaq Debut With 473 Million XRP Treasury 
Amazon Eyes $8 Billion Nvidia Chip Spinoff to Fund AI Expansion 
Lynas Shares Slide on A$968 Million Meteoric Resources Deal 
Ripple Locks 700 Million XRP Back in Escrow After October Release 
Citi Raises Bitcoin Price Target to $113,000 on ETF Optimism 
Nike Stock Slides as Revenue Miss Clouds Turnaround 
WordPress Malware Uses Ethereum to Evade Removal 
AAVE, PUMP, WLD and SKY Rally as Crypto Market Slips 
 & Lead Plaintiff Deadline - March 27, 2017 - EconoTimes)
Add as a preferred source on Google
NEW YORK, March 23, 2017 -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against ReWalk Robotics Ltd. (“ReWalk” or the “Company”) (NASDAQ:RWLK) and certain of its officers, on behalf of a class who purchased ReWalk securities pursuant to the Company’s initial public offering (“IPO”) on or around September 12, 2014. Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/rwlk.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
ReWalk is a medical commercial bionic walking assistance system. The company designs, develops, and commercializes exoskeletons for wheelchair-bound individuals.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements in its Registration Statement and Prospectus issued in regards with the Initial Public Offering did not disclose material information, including that ReWalk could not comply with “special controls” requirements or to offer the U.S. Food and Drug Administration with a post market surveillance study. Once this information was made public, ReWalk stock price dropped, causing investors harm.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/rwlk or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in ReWalk you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
